Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GDUFA II: More Than 2,000 ANDAs Remain Unclaimed, Large Firms Still Dominate

Apr 17 2017

• By Derrick Gingery

Man with report

Related Content

Fresenius Steps Up International Ambition Through Akorn Pursuit

Apr 11 2017

Generic Industry Hit With Avalanche Of Price Fixing Suits

Feb 22 2017

GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval

Jun 16 2015

Generic Industry Consolidation Illustrated In ANDA Holder List

Dec 22 2016

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Sep 26 2016

ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'

Oct 23 2016

Related Companies

Zydus Pharmaceuticals (USA) Inc.

Akorn, Inc.

Fresenius SE & Co. KGaA

Teva Pharmaceutical Industries Ltd.

Viatris Inc.

Novartis AG

Novartis AG

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States FDA Generic Drugs Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window